[{"id":"4829b067-17e9-4303-a9f1-a51640780137","acronym":"","url":"https://clinicaltrials.gov/study/NCT07211737","created_at":"2025-10-11T01:28:20.312Z","updated_at":"2025-10-11T01:28:20.312Z","phase":"Phase 1","brief_title":"NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma","source_id_and_acronym":"NCT07211737","lead_sponsor":"Baylor College of Medicine","biomarkers":" NKG2D","pipe":"","alterations":" ","tags":["NKG2D"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2043","study_completion_date":" 12/01/2043","last_update_posted":"2025-10-08"},{"id":"e544b76d-26e2-4ad6-a6eb-87395873bc91","acronym":"","url":"https://clinicaltrials.gov/study/NCT07085338","created_at":"2025-08-02T14:49:08.314Z","updated_at":"2025-08-02T14:49:08.314Z","phase":"Phase 2","brief_title":"A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma","source_id_and_acronym":"NCT07085338","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan • Anktiva (nogapendekin alfa inbakicept-pmln) • Leukine (sargramostim) • humanised dinutuximab (Hu14.18K322A)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2025-07-25"},{"id":"26646272-f3f1-4cb9-84dd-16ded62b0796","acronym":"","url":"https://clinicaltrials.gov/study/NCT01875601","created_at":"2021-01-29T07:04:49.340Z","updated_at":"2025-02-25T12:36:34.409Z","phase":"Phase 1","brief_title":"NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors","source_id_and_acronym":"NCT01875601","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 06/11/2013","start_date":" 06/11/2013","primary_txt":" Primary completion: 09/08/2015","primary_completion_date":" 09/08/2015","study_txt":" Completion: 09/08/2015","study_completion_date":" 09/08/2015","last_update_posted":"2025-02-24"},{"id":"79649cc6-d582-4cf7-94a7-6b84b6103cab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04901702","created_at":"2021-05-25T18:52:49.387Z","updated_at":"2025-02-25T12:28:07.986Z","phase":"Phase 1/2","brief_title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","source_id_and_acronym":"NCT04901702","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" EWSR1 • FLI1","pipe":"","alterations":" ","tags":["EWSR1 • FLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 06/09/2021","start_date":" 06/09/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"5aa1495f-1183-4095-b05a-503274e48528","acronym":"","url":"https://clinicaltrials.gov/study/NCT04936529","created_at":"2021-06-23T17:52:37.826Z","updated_at":"2025-02-25T13:53:51.961Z","phase":"Phase 2","brief_title":"A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma","source_id_and_acronym":"NCT04936529","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYC • MYCN • CSF2","pipe":" | ","alterations":" MYCN amplification","tags":["MYC • MYCN • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 286","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2025-02-20"},{"id":"52425dc1-74c8-49b8-8efe-2388d72e2562","acronym":"","url":"https://clinicaltrials.gov/study/NCT06172296","created_at":"2023-12-15T20:18:48.678Z","updated_at":"2025-02-25T14:04:06.256Z","phase":"Phase 3","brief_title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","source_id_and_acronym":"NCT06172296","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • TERT • MYCN","pipe":"","alterations":" ","tags":["ALK • TERT • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane"],"overall_status":"Recruiting","enrollment":" Enrollment 478","initiation":"Initiation: 04/19/2024","start_date":" 04/19/2024","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-02-19"},{"id":"624dd6dc-cc83-4a6f-bc36-82aa836ef4f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05429502","created_at":"2022-06-23T16:00:07.143Z","updated_at":"2025-02-25T14:08:56.594Z","phase":"Phase 1/2","brief_title":"Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors","source_id_and_acronym":"NCT05429502","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MYCN • SMARCB1","pipe":" | ","alterations":" IDH wild-type","tags":["MYCN • SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Kisqali (ribociclib) • topotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 231","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 10/15/2027","primary_completion_date":" 10/15/2027","study_txt":" Completion: 01/28/2028","study_completion_date":" 01/28/2028","last_update_posted":"2025-02-17"},{"id":"730375bc-d48c-47d0-ba52-87fbeb8848b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02868268","created_at":"2021-01-18T14:04:46.668Z","updated_at":"2025-02-25T14:14:50.518Z","phase":"","brief_title":"Neuroblastoma Precision Trial","source_id_and_acronym":"NCT02868268","lead_sponsor":"New Approaches to Neuroblastoma Therapy Consortium","biomarkers":" PD-L1 • ALK","pipe":"","alterations":" ","tags":["PD-L1 • ALK"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 08/22/2016","start_date":" 08/22/2016","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-17"},{"id":"74915413-c151-4ff8-ac18-adfbd918fb7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06000787","created_at":"2023-08-21T15:09:02.705Z","updated_at":"2025-02-25T14:09:59.668Z","phase":"","brief_title":"MCT for the Harvard/UCSF ROBIN Center","source_id_and_acronym":"NCT06000787","lead_sponsor":"Brigham and Women's Hospital","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Azedra (iobenguane I 131)"],"overall_status":"Recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 09/19/2023","start_date":" 09/19/2023","primary_txt":" Primary completion: 08/31/2028","primary_completion_date":" 08/31/2028","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-02-17"},{"id":"10304746-18e0-4d88-842a-1ac84cd23992","acronym":"","url":"https://clinicaltrials.gov/study/NCT02176967","created_at":"2021-01-18T10:09:07.743Z","updated_at":"2025-02-25T15:10:08.662Z","phase":"Phase 3","brief_title":"Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma","source_id_and_acronym":"NCT02176967","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN","pipe":"","alterations":" ","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 621","initiation":"Initiation: 08/08/2014","start_date":" 08/08/2014","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-13"},{"id":"149819dc-f2ee-4b82-83e1-8c607402853f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02909777","created_at":"2021-01-18T14:16:53.862Z","updated_at":"2025-02-25T14:50:16.761Z","phase":"Phase 1","brief_title":"Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma","source_id_and_acronym":"NCT02909777","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MYC • MYCN","pipe":" | ","alterations":" MYCN expression","tags":["MYC • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fimepinostat (CUDC-907)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-13"},{"id":"4b1b80e8-bcd8-4a78-8ae1-fe238c0362b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126916","created_at":"2021-01-18T15:24:54.957Z","updated_at":"2025-02-25T15:10:35.328Z","phase":"Phase 3","brief_title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","source_id_and_acronym":"NCT03126916","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 724","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-13"},{"id":"f48f1b5b-016c-486a-b2f8-c14558815182","acronym":"","url":"https://clinicaltrials.gov/study/NCT03794349","created_at":"2023-11-21T16:15:50.470Z","updated_at":"2025-02-25T15:11:00.647Z","phase":"Phase 2","brief_title":"Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma","source_id_and_acronym":"NCT03794349","lead_sponsor":"Children's Oncology Group","biomarkers":" IFNG • IL6 • CD276 • TNFA","pipe":"","alterations":" ","tags":["IFNG • IL6 • CD276 • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 07/08/2019","start_date":" 07/08/2019","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-13"},{"id":"13a8ea63-40e9-404c-b670-688e9b2c8b54","acronym":"LuDO-N","url":"https://clinicaltrials.gov/study/NCT04903899","created_at":"2021-05-27T13:53:06.417Z","updated_at":"2025-02-25T15:26:53.866Z","phase":"Phase 2","brief_title":"177Lutetium-DOTATATE in Children with Primary Refractory or Relapsed High-risk Neuroblastoma","source_id_and_acronym":"NCT04903899 - LuDO-N","lead_sponsor":"Jakob Stenman","biomarkers":" SSTR • CD34 • SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR Expression","tags":["SSTR • CD34 • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 05/20/2026","primary_completion_date":" 05/20/2026","study_txt":" Completion: 05/20/2031","study_completion_date":" 05/20/2031","last_update_posted":"2025-02-11"},{"id":"9ca08e6c-d47d-4698-95f5-d5e3748cdfe5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213691","created_at":"2021-01-18T15:51:28.406Z","updated_at":"2025-02-25T16:44:10.128Z","phase":"Phase 2","brief_title":"Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213691","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 10/30/2017","start_date":" 10/30/2017","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2025-02-05"},{"id":"71628f3d-27a7-487c-a8bd-86587a5fa22b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00026312","created_at":"2023-11-21T19:15:23.482Z","updated_at":"2025-02-25T16:50:44.915Z","phase":"Phase 3","brief_title":"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma","source_id_and_acronym":"NCT00026312","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYCN • NCR3LG1","pipe":"","alterations":" ","tags":["MYCN • NCR3LG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin) • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1449","initiation":"Initiation: 10/18/2001","start_date":" 10/18/2001","primary_txt":" Primary completion: 01/12/2012","primary_completion_date":" 01/12/2012","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-04"},{"id":"76e5fabc-947c-4440-ba90-48fba05bcaa1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01850888","created_at":"2021-01-18T08:15:43.798Z","updated_at":"2025-02-25T16:51:18.108Z","phase":"","brief_title":"MIBG for Refractory Neuroblastoma and Pheochromocytoma","source_id_and_acronym":"NCT01850888","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" IL6 • IL2","pipe":"","alterations":" ","tags":["IL6 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Azedra (iobenguane I 131)"],"overall_status":"Suspended","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-04"},{"id":"a960e964-3a5f-401a-844c-ae8dd61b3da6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213704","created_at":"2023-12-06T19:15:43.766Z","updated_at":"2025-02-25T16:51:56.748Z","phase":"Phase 2","brief_title":"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213704","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 08/23/2017","start_date":" 08/23/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 10/08/2025","study_completion_date":" 10/08/2025","last_update_posted":"2025-02-04"},{"id":"d62d79f2-de52-4433-b2e3-056a8d934f77","acronym":"","url":"https://clinicaltrials.gov/study/NCT02650648","created_at":"2021-01-18T12:54:13.814Z","updated_at":"2025-02-25T16:51:37.215Z","phase":"Phase 1","brief_title":"Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma","source_id_and_acronym":"NCT02650648","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Danyelza (naxitamab-gqgk) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-04"},{"id":"e098103f-75c1-4aa9-b386-41c1d51fb602","acronym":"MATCH","url":"https://clinicaltrials.gov/study/NCT03155620","created_at":"2021-01-18T15:33:32.929Z","updated_at":"2025-02-25T16:51:52.930Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","source_id_and_acronym":"NCT03155620 - MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2316","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-04"},{"id":"96a46201-6c05-499a-b5e8-480c4ba52158","acronym":"","url":"https://clinicaltrials.gov/study/NCT03382158","created_at":"2021-01-18T16:41:19.886Z","updated_at":"2025-02-25T17:29:36.962Z","phase":"","brief_title":"International PPB/DICER1 Registry","source_id_and_acronym":"NCT03382158","lead_sponsor":"Children's Hospitals and Clinics of Minnesota","biomarkers":" DICER1","pipe":"","alterations":" ","tags":["DICER1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 3400","initiation":"Initiation: 12/06/2016","start_date":" 12/06/2016","primary_txt":" Primary completion: 12/06/2030","primary_completion_date":" 12/06/2030","study_txt":" Completion: 12/06/2035","study_completion_date":" 12/06/2035","last_update_posted":"2025-01-30"},{"id":"7918a7a6-96c5-4624-85f3-798790d9ac5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06703944","created_at":"2025-02-26T10:34:57.875Z","updated_at":"2025-02-26T10:34:57.875Z","phase":"","brief_title":"Risk Model for Metastasis Detection of Neuroblastoma","source_id_and_acronym":"NCT06703944","lead_sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" PTPRC • NCAM1 • CD81","pipe":"","alterations":" ","tags":["PTPRC • NCAM1 • CD81"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 500","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-12-04"},{"id":"9f54073b-404a-456d-9f9e-2ad505dd2ab3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06500819","created_at":"2025-02-26T14:37:02.227Z","updated_at":"2025-02-26T14:37:02.227Z","phase":"Phase 1","brief_title":"Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors","source_id_and_acronym":"NCT06500819","lead_sponsor":"Stanford University","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 07/11/2024","start_date":" 07/11/2024","primary_txt":" Primary completion: 07/01/2029","primary_completion_date":" 07/01/2029","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2024-10-31"},{"id":"c2c40e25-bf03-4412-bf0e-9712fe410547","acronym":"","url":"https://clinicaltrials.gov/study/NCT04947501","created_at":"2021-07-01T14:54:45.053Z","updated_at":"2024-07-02T16:34:27.282Z","phase":"Phase 1","brief_title":"A Study of N9 Chemotherapy in Children With Neuroblastoma","source_id_and_acronym":"NCT04947501","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • topotecan • mesna • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 06/22/2025","primary_completion_date":" 06/22/2025","study_txt":" Completion: 06/22/2025","study_completion_date":" 06/22/2025","last_update_posted":"2024-06-11"}]